Business Segments Scinai Immunotherapeutics Ltd.
Stocks
SCNI
US09073Q3039
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2498 USD | -1.65% |
|
-0.36% | -64.92% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Pharmaceuticals | - | - | - | 658K | 1.31M | |||||
Total Assets | 99.6M | 27.07M | 17.47M | 13.45M | 11.63M | |||||
Interest Expense | -10.83M | -4.89M | - | -1.42M | -359K | |||||
CAPEX | -430K | -836K | -637K | -12K | -24K | |||||
EBT | -39.98M | -5.8M | -6.5M | 4.8M | -8.31M | |||||
Gross Profit | - | - | - | -580K | -2.65M | |||||
D&A | 2.42M | 562K | 514K | 1.65M | 1.42M | |||||
Operating Income | -34.83M | - | - | -8.64M | -7.54M | |||||
Net Income | -39.98M | -5.8M | -6.5M | 4.8M | -8.31M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Israel | - | - | - | 658K | 1.31M | |||||
Total Assets | 99.6M | 27.07M | 17.47M | 13.45M | 11.63M | |||||
Interest Expense | -10.83M | -4.89M | - | -1.42M | -359K | |||||
D&A | 2.42M | 562K | 514K | 1.65M | 1.42M | |||||
CAPEX | -430K | -836K | -637K | -12K | -24K | |||||
Gross Profit | - | - | - | -580K | -2.65M | |||||
Net Income | -39.98M | -5.8M | -6.5M | 4.8M | -8.31M | |||||
EBT | -39.98M | -5.8M | -6.5M | 4.8M | -8.31M | |||||
Operating Income | -34.83M | - | - | -8.64M | -7.54M |
- Stock Market
- Stocks
- SCNI Stock
- Financials Scinai Immunotherapeutics Ltd.
- Business Segments
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
